For Evie Junior, living with sickle cell disease has been like running a marathon. “But it’s a marathon where as you keep going, the trail gets rockier and
Immune-system T cells have been reprogrammed into regenerative stem cell-like memory (TSCM) cells that are long-lived, highly active “super immune cells” with strong antitumor activity, according to new
The colorful pictures of the whole mouse brain at different ages are the first of their kind and a pivotal step forward in understanding behavior, scientists say. Findings—published
Researchers from the group of Catherine Robin at the Hubrecht Institute have characterized the molecular landscape of the aorta that supports the generation of the first hematopoietic stem
In this Oncotarget study, the authors test a novel anti-CEACAM antibody conjugated to a fluorescent dye for detection of multiple CEACAM antigens to enhance visualization of colorectal PDOX
A team led by researchers at Baylor College of Medicine found that not only do individual mammalian cells in a population fail to respond synchronously to estrogen stimulation,
An international consortium of researchers from Australia, Ireland, the UK, Europe, and Canada, has painstakingly mapped an intracellular network that could open the door to discovering new targeted
Patients with non-small cell lung cancer (NSCLC) now have more improved treatment options compared to standard of care with the addition of several new agents called immune-checkpoint inhibitors
Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Mannheim University Medical Center have now discovered that a certain group of cancer drugs (MEK Inhibitors)
TUESDAY, Dec. 4, 2018 — A new gene therapy shows early promise against sickle cell anemia, researchers say. The therapy targets the genetic flaw that causes sickle cell.
We and our partners use cookies on this site to improve our service, perform analytics, personalize advertising, measure advertising performance, and remember website preferences.Ok
